Cargando…

Mifepristone Antagonization with Progesterone to Avert Medication Abortion: A Scoping Review

The safety and efficacy of mifepristone antagonization with progesterone to avert medication abortion, also known as abortion pill rescue, is a subject of vigorous debate. Two prominent medical associations have taken positions that either entirely reject or fully support its use. This scoping revie...

Descripción completa

Detalles Bibliográficos
Autor principal:	DeBeasi, Paul L. C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638961/ https://www.ncbi.nlm.nih.gov/pubmed/37969420 http://dx.doi.org/10.1177/00243639231176592

Ejemplares similares

Medication Abortion With Pharmacist Dispensing of Mifepristone
por: Grossman, Daniel, et al.
Publicado: (2021)

The efficacy and influence factors analysis of Mifepristone combined with estrogen-progesterone in the treatment of incomplete abortion
por: Wang, Kai, et al.
Publicado: (2022)

Implementing medical abortion with mifepristone and misoprostol in Norway 1998–2013
por: Løkeland, Mette, et al.
Publicado: (2017)

Comparing telemedicine to in-clinic medication abortions induced with mifepristone and misoprostol
por: Wiebe, Ellen R, et al.
Publicado: (2020)

Dispensing mifepristone for medical abortion in Canada: Pharmacists’ experiences of the first year
por: Zusman, Enav Z., et al.
Publicado: (2023)

Medical abortion with mifepristone and home administration of misoprostol up to 63 days’ gestation
por: Løkeland, Mette, et al.
Publicado: (2014)

Early medical abortion with self‐administered low‐dose mifepristone in combination with misoprostol
por: Song, Li‐Ping, et al.
Publicado: (2018)

The future of abortion is now: Mifepristone by mail and in-clinic abortion access in the United States
por: Mark, Alice, et al.
Publicado: (2021)

Pharmacist direct dispensing of mifepristone for medication abortion in Canada: a survey of community pharmacists
por: Zusman, Enav Z, et al.
Publicado: (2022)

Pharmacist checklist and resource guide for mifepristone medical abortion: User-centred development and testing
por: Rebic, Nevena, et al.
Publicado: (2021)

The use of mifepristone in abortion associated with an increased risk of uterine leiomyomas
por: Shen, Qi, et al.
Publicado: (2017)

X-Ray Crystal Structure of the Ancestral 3-Ketosteroid Receptor–Progesterone–Mifepristone Complex Shows Mifepristone Bound at the Coactivator Binding Interface
por: Colucci, Jennifer K., et al.
Publicado: (2013)

Comparison of mifepristone plus misoprostol with misoprostol alone for first trimester medical abortion: A systematic review and meta-analysis
por: Shimels, Tariku, et al.
Publicado: (2023)

Implementation of mifepristone medical abortion in Canada: pilot and feasibility testing of a survey to assess facilitators and barriers
por: Devane, Courtney, et al.
Publicado: (2019)

Maternal-fetal conflict averted by progesterone- induced FOXP3+ regulatory T cells
por: Severance, Ashley L., et al.
Publicado: (2022)

Trends in medication abortion and the role of low-volume and nonmetropolitan mifepristone purchasers: 2008–2011 and 2014–2017()
por: Jones, Rachel K.
Publicado: (2020)

Cost of goods sold analysis and recommendations to reduce costs of co-packaged mifepristone–misoprostol for medical abortion
por: Chinery, Lester, et al.
Publicado: (2020)

Clinical Efficacy and Safety Study of Mifepristone with Misoprostol Treatment in Patients with Missed Abortion
por: Zhao, Xiaoying, et al.
Publicado: (2021)

A Retrospective Cost-Effectiveness Analysis of Mifepristone–Misoprostol Medical Abortions in the First Year at the Regina General Hospital
por: Hunter, Caitlin, et al.
Publicado: (2021)

Mifepristone Plasma Level and Glucocorticoid Receptor Antagonism Associated With Response in Patients With Psychotic Depression
por: Block, Thaddeus, et al.
Publicado: (2017)

Characterization of Membrane-Associated Progesterone Receptor Component-2 (MAPRC2) from Trichinella spiralis and Its Interaction with Progesterone and Mifepristone
por: Aleem, Muhammad Tahir, et al.
Publicado: (2021)

Progesterone-mediated reversal of mifepristone-induced pregnancy termination in a rat model: an exploratory investigation
por: Camilleri, Christina, et al.
Publicado: (2023)

Subsequent placenta accreta after previous mifepristone-induced abortion: A case report
por: Zhao, Peng, et al.
Publicado: (2021)

Retracted: Clinical Efficacy and Safety Study of Mifepristone with Misoprostol Treatment in Patients with Missed Abortion
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Clinical Outcomes and Women’s Experiences before and after the Introduction of Mifepristone into Second-Trimester Medical Abortion Services in South Africa
por: Constant, Deborah, et al.
Publicado: (2016)

Activation function 1 of progesterone receptor is required for progesterone antagonism of oestrogen action in the uterus
por: Lee, Shi Hao, et al.
Publicado: (2022)

Determination of Mifepristone (RU-486) and Its Metabolites in Maternal Blood Sample after Pharmacological Abortion
por: Szpot, Paweł, et al.
Publicado: (2022)

Mifepristone (RU486) inhibits dietary lipid digestion by antagonizing the role of glucocorticoid receptor on lipase transcription
por: Ma, Peng, et al.
Publicado: (2021)

A Longitudinal Cohort Study of Emergency Room Utilization Following Mifepristone Chemical and Surgical Abortions, 1999–2015
por: Studnicki, James, et al.
Publicado: (2021)

Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression
por: Tieszen, Chelsea R, et al.
Publicado: (2011)

The progesterone antagonist mifepristone/RU486 blocks the negative effect on life span caused by mating in female Drosophila
por: Landis, Gary N., et al.
Publicado: (2015)

Exploring the impact of mifepristone’s risk evaluation and mitigation strategy (REMS) on the integration of medication abortion into US family medicine primary care clinics()
por: Razon, Na’amah, et al.
Publicado: (2022)

Author Correction: Activation function 1 of progesterone receptor is required for progesterone antagonism of oestrogen action in the uterus
por: Lee, Shi Hao, et al.
Publicado: (2023)

Abortion metrics: a scoping review of abortion measures and indicators
por: Filippi, Veronique, et al.
Publicado: (2021)

EXPRESSION OF CONCERN: A Longitudinal Cohort Study of Emergency Room Utilization Following Mifepristone Chemical and Surgical Abortions
Publicado: (2023)

Mifepristone-Induced Hypothyroidism
por: Kalara, Niketa, et al.
Publicado: (2023)

Averting Disease
Publicado: (1860)

Averting Disease
Publicado: (1876)

Interstitial Ectopic Pregnancy: The Role of Mifepristone in the Medical Treatment
por: Stabile, Guglielmo, et al.
Publicado: (2021)

Novel RU486 (mifepristone) analogues with increased activity against Venezuelan Equine Encephalitis Virus but reduced progesterone receptor antagonistic activity
por: DeBono, Aaron, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_r9ts22kuoket6j4nt3gnkm4iir